Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal Pegcetacoplan (APL-2) for Patients With Wet AMD
Status:
Completed
Trial end date:
2016-03-08
Target enrollment:
Participant gender:
Summary
The objective of this study is to provide initial safety, tolerability and pharmacokinetics
information of intravitreal administration of pegcetacoplan in order to support further
development into larger Phase II studies for treatment of patients with AMD.